Le site du DES d'oncologie de Toulouse

Hématologie

8 articles et aucun document

Articles
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
Hématologie - Publié le 23/06/2019 par Gauthier Glemarec

International guidelines recommend that positron emission tomography-computed tomography (PET-CT) should replace CT in Hodgkin lymphoma (HL). The aims of this study were to compare PET-CT with CT fo... lire la suite


High burden of subsequent malignant neoplasms and cardiovascular disease in longterm Hodgkin lymphoma survivors
Hématologie - Publié le 23/06/2019 par Gauthier Glemarec

Hodgkin lymphoma (HL) patients are at an increased risk of late adverse treatment effects. While published studies focussed on the risk of either subsequent malignant neoplasms (SMNs) or cardiovascul... lire la suite


Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
Hématologie - Publié le 23/06/2019 par Gauthier Glemarec

Survivors of Hodgkin’s lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late 1980s, on the long-term risk... lire la suite


Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Hématologie - Publié le 23/06/2019 par Gauthier Glemarec

Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improv... lire la suite


Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score $ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
Hématologie - Publié le 23/06/2019 par Gauthier Glemarec

To compare patients with high-risk stage III to IV Hodgkin lymphoma (HL) in the phase III European Organisation for Research and Treatment of Cancer 20012 Intergroup trial (Comparison of Two Combinat... lire la suite


Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Hématologie - Publié le 23/06/2019 par Gauthier Glemarec

The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin’s lymphoma has been unclear. We did a prospective randomised clinical trial comparing two ... lire la suite


Involved-field radiotherapy [...] : Results of the HD8 trial of the german hodgkin's lymphoma study group
Hématologie - Publié le 23/06/2019 par Gauthier Glemarec

Extended fiel vs involved field after 4 cycles of chemotherapy... lire la suite


Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Hématologie - Publié le 23/06/2019 par Gauthier Glemarec

Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been approved for relapsed and refractory Hodgkin’s lymphoma.... lire la suite